Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
GASTROENTEROLOGY / SYSTEMATIC REVIEW/META-ANALYSIS
Efficacy and safety of proton pump inhibitors for diabetes mellitus in patients with gastroesophageal reflux disease: a meta-analysis
1
Department of Endocrinology, Dongying People’s Hospital, Dongying, Shandong, China
2
Department of Pharmacy, Dongying People’s Hospital, Dongying, Shandong, China
These authors had equal contribution to this work
Submission date: 2024-05-22
Final revision date: 2024-07-23
Acceptance date: 2024-08-05
Online publication date: 2024-09-07
Corresponding author
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Gastroesophageal reflux disease (GERD) is prevalent in patients with type 2 diabetes mellitus (T2DM). The use of proton pump inhibitors (PPIs) is recognized as an effective method to reduce gastric acid secretion in patients with GERD. Nevertheless, whether PPIs are effective or safe for the treatment of T2DM complicated by GERD remains unknown.
Material and methods:
To assess the efficacy and safety of PPIs in the management of T2DM complicated with GERD, databases including Web of Science, Cochrane Library, PubMed, and Embase were comprehensively searched for randomized controlled trials (RCTs) focusing on the treatment of T2DM complicated with GERD published before December 2023. Following data extraction and quality assessment, outcomes, including endoscopic efficiency, fasting blood glucose (FBG), symptom relief rates, levels of glycosylated hemoglobin A1c (HbA1c), and the incidence of adverse reactions, were analyzed using RevMan 5.4.
Results:
The results suggest that the PPI group exhibited a higher efficacy rate compared to the control group in endoscopic efficiency (69.32% vs. 5.45%, OR = 40.50, 95% CI: 18.77–87.39) and symptom relief rates (92.94% vs. 54.65%, OR = 6.45, 95% CI: 3.41–12.20). Furthermore, PPI treatment was associated with a significant reduction in HbA1c levels (weighted mean difference [WMD] = –0.41, 95% CI: –0.68 to –0.14) and FBG levels (WMD = –10.15 mg/dl, 95% CI: –19.64 to –0.66) in patients with T2DM complicated with GERD. In terms of safety, the incidence of adverse reactions was not significantly different between the two groups (PPI group: 10.78% vs. control group:11.88%, p > 0.05).
Conclusions:
PPIs can effectively improve the glycemic control of patients with T2DM complicated with GERD.
Gastroesophageal reflux disease (GERD) is prevalent in patients with type 2 diabetes mellitus (T2DM). The use of proton pump inhibitors (PPIs) is recognized as an effective method to reduce gastric acid secretion in patients with GERD. Nevertheless, whether PPIs are effective or safe for the treatment of T2DM complicated by GERD remains unknown.
Material and methods:
To assess the efficacy and safety of PPIs in the management of T2DM complicated with GERD, databases including Web of Science, Cochrane Library, PubMed, and Embase were comprehensively searched for randomized controlled trials (RCTs) focusing on the treatment of T2DM complicated with GERD published before December 2023. Following data extraction and quality assessment, outcomes, including endoscopic efficiency, fasting blood glucose (FBG), symptom relief rates, levels of glycosylated hemoglobin A1c (HbA1c), and the incidence of adverse reactions, were analyzed using RevMan 5.4.
Results:
The results suggest that the PPI group exhibited a higher efficacy rate compared to the control group in endoscopic efficiency (69.32% vs. 5.45%, OR = 40.50, 95% CI: 18.77–87.39) and symptom relief rates (92.94% vs. 54.65%, OR = 6.45, 95% CI: 3.41–12.20). Furthermore, PPI treatment was associated with a significant reduction in HbA1c levels (weighted mean difference [WMD] = –0.41, 95% CI: –0.68 to –0.14) and FBG levels (WMD = –10.15 mg/dl, 95% CI: –19.64 to –0.66) in patients with T2DM complicated with GERD. In terms of safety, the incidence of adverse reactions was not significantly different between the two groups (PPI group: 10.78% vs. control group:11.88%, p > 0.05).
Conclusions:
PPIs can effectively improve the glycemic control of patients with T2DM complicated with GERD.
REFERENCES (33)
1.
Clarrett DM, Hachem C. Gastroesophageal reflux disease (GERD). Mo Med 2018; 115: 214-8.
2.
Săraru ER, Enciu V, Peagu R, Fierbinţeanu-Braticevici C. Advances in the diagnosis of GERD. Rom J Intern Med 2021; 59: 3-9.
3.
Dağlı Ü, Kalkan İ H. The role of lifestyle changes in gastroesophageal reflux diseases treatment. Turk J Gastroenterol 2017; 28 (Suppl 1): S33-7.
4.
Sethi S, Richter JE. Diet and gastroesophageal reflux disease: role in pathogenesis and management. Curr Opin Gastroenterol 2017; 33: 107-11.
5.
Taraszewska A. Risk factors for gastroesophageal reflux disease symptoms related to lifestyle and diet. Rocz Panstw Zakl Hig 2021; 72: 21-8.
6.
Yan Y, Wu T, Zhang M, Li C, Liu Q, Li F. Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population. BMC Public Health 2022; 22: 1382.
7.
Punjabi P, Hira A, Prasad S, Wang X, Chokhavatia S. Review of gastroesophageal reflux disease (GERD) in the diabetic patient. J Diabetes 2015; 7: 599-609.
8.
Maev IV, Iurenev GL, Kakhramanova DA. [Peculiarities of gastroesophageal reflux disease in patients with type 2 diabetes mellitus]. Klin Med (Mosk) 2012; 90: 53-6.
9.
AlTassan FM, Al-Khowaiter SS, Alsubki HE, Alhamoud WA, Niazi AK, AlJarallah BM. Prevalence of gastro-esophageal reflux in diabetic patients at a tertiary hospital in Central Saudi Arabia. Saudi Med J 2020; 41: 151-6.
10.
Yuan S, Larsson SC. Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux disease: a Mendelian randomization study. Eur J Epidemiol 2022; 37: 747-54.
11.
Chen J, Yuan S, Fu T, et al. Gastrointestinal consequences of type 2 diabetes mellitus and impaired glycemic homeostasis: a mendelian randomization study. Diabetes Care 2023; 46: 828-35.
12.
Mitrovic B, Gluvic ZM, Obradovic M, et al. Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? Arch Med Sci 2023; 19: 884-94.
13.
Ruan X, Chen J, Sun Y, et al. Depression and 24 gastrointestinal diseases: a Mendelian randomization study. Transl Psychiatry 2023; 13: 146.
14.
Negovan A, Banescu C, Pantea M, Simona B, Mocan S, Iancu M. Factors associated with gastro-duodenal ulcer in compensated type 2 diabetic patients: a Romanian single-center study. Arch Med Sci 2022; 18: 45-51.
15.
Rajput MA, Ali F, Zehra T, Zafar S, Kumar G. The effect of proton pump inhibitors on glycaemic control in diabetic patients. J Taibah Univ Med Sci 2020; 15: 218-23.
16.
Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA 2020; 324: 2536-47.
17.
Yadlapati R, DeLay K. Proton pump inhibitor-refractory gastroesophageal reflux disease. Med Clin North Am 2019; 103: 15-27.
18.
Monreal-Robles R, Remes-Troche JM. Diabetes and the esophagus. Curr Treat Options Gastroenterol 2017; 15: 475-89.
19.
Careyva B, Stello B. Diabetes mellitus: management of gastrointestinal complications. Am Fam Physician 2016; 94: 980-6.
20.
Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am 2013; 42: 809-32.
21.
Okdahl T, Bertoli D, Brock B, et al. Study protocol for a multicentre, randomised, parallel group, sham-controlled clinical trial investigating the effect of transcutaneous vagal nerve stimulation on gastrointestinal symptoms in people with diabetes complicated with diabetic autonomic neuropathy: the DAN-VNS Study. BMJ Open 2021; 11: e038677.
22.
Schnoll-Sussman F, Niec R, Katz PO. Proton pump inhibitors: the good, bad, and ugly. Gastrointest Endosc Clin N Am 2020; 30: 239-51.
23.
Villegas K, Meier JL, Long M, Lopez J, Swislocki A. The effect of proton pump inhibitors on glycemic control in patients with type 2 diabetes. Metab Syndr Relat Disord 2019; 17: 192-6.
24.
Han N, Oh M, Park SM, et al. The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus. Can J Diabetes 2015; 39: 24-8.
25.
Barchetta I, Guglielmi C, Bertoccini L, et al. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetol 2015; 52: 873-80.
26.
Crouch MA, Mefford IN, Wade EU. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J Am Board Fam Med 2012; 25: 50-4.
27.
Singh PK, Hota D, Dutta P, et al. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2012; 97: E2105-8.
28.
Hove KD, Brøns C, Færch K, et al. Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia 2013; 56: 22-30.
29.
Takebayashi K, Sakurai S, Suzuki T, et al. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes. Endocr J 2014; 61: 1031-9.
30.
González-Ortiz M, Martínez-Abundis E, Mercado-Sesma AR, Álvarez-Carrillo R. Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2015; 108: e11-3.
31.
Agrawal PK, Chandra S, Jaiswal AK, Gautam A, Maheshwari PK. Study of the effect of pantoprazole on glycemic control of type-2 diabetes mellitus in tertiary care center and hospital in North India. J Med Tropics 2018; 20: 1-5.
32.
Bozkuş Y, Mousa U, İyidir Ö T, et al. Short-term effect of hypergastrinemia following esomeprazole treatment on well-controlled type 2 diabetes mellitus: a prospective study. Endocr Metab Immune Disord Drug Targets 2020; 20: 1090-6.
33.
Al-Bachaji IN, Al-Buhadiliy AK, Al-Kuraishy HM, Al-Gareeb AI. Proton pump inhibitors regulate metabolic profile and glycaemic indices in patients with type 2 diabetes mellitus: a rising dawn of a new therapeutic concept. J Pak Med Assoc 2019; 69 (Suppl 3): S31-5.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
